Trividia Health, Inc. Announces Preferred Listing of the TRUE METRIX® Blood Glucose Meter and Test Strips for Pennsylvania's Medicaid Recipients
The TRUE METRIX ® portfolio provides a level of performance rooted in science, research and continuous technological advancements. TRUE METRIX Test Strips feature TRIPLE SENSE TECHNOLOGY ®, which ensures clinically accuracy and confidence in results.
TRUE METRIX Test Strips are made in the United States, with manufacturing facilities in Fort Lauderdale, Florida. Trividia Health is the largest US manufacturer of pharmacy branded products for people with diabetes.
For over 40 years, Trividia Health has been unwavering in its commitment to advance diabetes care. Our team is driven to provide innovative and affordable solutions to help the millions of people living with diabetes manage their blood glucose levels.
'Alongside our pharmacy and distribution partners, Trividia Health's priority is providing accessibility through national coverage with a local presence. Having the TRUE METRIX Self-Monitoring Blood Glucose Meters and Test Strips as preferred products within Pennsylvania allows patients the ability to test with confidence and manage their diabetes,' said Jonathan Chapman, President and CEO of Trividia Health.
The TRUE METRIX products are widely available throughout Pennsylvania and are sold under the TRUE METRIX brand name as well as the brand names of the nation's premier retail drug stores, distributors, and independent pharmacies.
About Trividia Health
Trividia Health, Inc., is a global health and wellness company based in Fort Lauderdale, Florida and a leading developer, manufacturer and marketer of advanced performance and digital management products for people with diabetes. With products sold under TRUE and store brand labels, the company is the partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world's leading retail pharmacies, distributors and mail service providers. For more information, please visit: www.TrividiaHealth.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Swisslog Healthcare Elevates Jennie McQuade to Global Chief Legal Counsel & Privacy Officer
BROOMFIELD, Colo.--(BUSINESS WIRE)-- Swisslog Healthcare, a global leader in pharmacy and transport automation solutions, announces the promotion of Jennie McQuade to Global Chief Legal Counsel & Privacy Officer. This appointment recognizes McQuade's decade-long commitment to enhancing data security and privacy in the healthcare industry. "Jennie's leadership has been instrumental in strengthening our security posture and navigating complex global privacy regulations.' said Cory Kwarta, CEO of Swisslog Healthcare. 'As we continue to innovate, Jennie's oversight will help us to maintain the highest standards of data security for our clients worldwide." McQuade's promotion comes after successfully leading Swisslog Healthcare to achieve significant milestones in data protection. Under her guidance, the company completed the SOC 2 Type 2 Examination and secured HITRUST risk-based certification for TransLogic, a Swisslog Healthcare company. "Our commitment to data security and privacy will enable our team to address the evolving standards of information security for global healthcare technology", said Jennie McQuade, Global Chief Legal Counsel & Privacy Officer, at Swisslog Healthcare. "As the industry continues its digital transformation, our work becomes increasingly important." In her expanded role, McQuade will oversee global legal operations, privacy initiatives, and cybersecurity strategies. Her expertise in implementing international, multilanguage training programs and comprehensive compliance communications will be instrumental in maintaining Swisslog Healthcare's position as a leader in healthcare technology security. About Swisslog Healthcare Swisslog Healthcare provides integrated medication supply chain solutions to hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patients' needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways. For more information, visit
Business Wire
4 hours ago
- Business Wire
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. 'Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx,' said John Hanna, CEO of CareDx. 'His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase.' In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. 'On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO,' said John Hanna. 'Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best.' About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
4 hours ago
- Business Wire
Stoke Therapeutics to Present at the Canaccord Genuity 45 th Annual Growth Conference
BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Using Stoke's proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke's first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke's initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke's proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit
